Bavarian Nordic: State gains from vaccine support capped by contract

Bavarian Nordic's potential corona vaccine will not be a gold mine investment for the Danish state, the biotech company's CFO says, as their agreement includes a cap on royalties.


After obtaining EUR 108m (DKK 800m) in financial aid from the Danish state, Bavarian Nordic has the opportunity to create a lucrative business before the state wants any of that money back.

The biotech company is only required to repay the money when sales reach a pre-defined level, and the state will only profit on its investment if sales are particularly good. Returns are also capped.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs